Insider · CIK 0001600946
Douglas Plassche
Files at ELTP (ELITE PHARMACEUTICALS INC /NV/). First filing Oct 28, 2024, latest Oct 3, 2025.
In brief
Douglas Plassche files SEC Form 4 as officer at ELTP (ELITE PHARMACEUTICALS INC /NV/). Since Oct 28, 2024, Douglas Plassche has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.2M, the latest filed on Oct 3, 2025.
A track record needs three past buys with six months of prices behind them; Douglas Plassche has 0, so none is measured yet.
The newest scored trade: sold $499k of ELTP on Oct 2, 2025, filed Oct 3, 2025, scored 38 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ELTP: ELITE PHARMACEUTICALS INC /NV/
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | ELTPsell ELITE PHARMACEUTICALS INC /NV/ | $499k 800,000 shares | -19% | +100% from low-17% from high | |
| 25Weak | ELTPsell ELITE PHARMACEUTICALS INC /NV/ | $116k 200,000 shares | -8% | +84% from low-23% from high | |
| 54Moderate | ELTPsell ELITE PHARMACEUTICALS INC /NV/ | $562k 1,133,932 shares | -100% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 22, 2025 | ELTP ELITE PHARMACEUTICALS INC /NV/ | 100,000 0.01% of outstanding | $555k | Aug 22, 2025 | $116k |
| Jul 8, 2025 | ELTP ELITE PHARMACEUTICALS INC /NV/ | 500,000 0.05% of outstanding | $303k | Jul 8, 2025 | none |
| Oct 23, 2024 | ELTP ELITE PHARMACEUTICALS INC /NV/ | 1,133,932 0.11% of outstanding | $680k | Oct 23, 2024 | none |
Transactions
Every row this insider has filed, 8 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | ELTP ELITE PHARMACEUTICALS INC /NV/ | MOption exercise Stock Options (right to buy) | +2,500,000 | $0.03 | $75k | 6,000,000 | Jan 13, 2026 |
| Jan 9, 2026 | ELTP ELITE PHARMACEUTICALS INC /NV/ | MOption exercise Stock Options (right to buy)derivative | -2,500,000 | $0.00 | $0 | 0 | Jan 13, 2026 |
| Oct 2, 2025 | ELTP ELITE PHARMACEUTICALS INC /NV/ | SOpen-market sale common stock | -800,000 | $0.62 | $499k | 3,500,000 | Oct 3, 2025 |
| Jul 8, 2025 | ELTP ELITE PHARMACEUTICALS INC /NV/ | SOpen-market sale Stock Options (right to buy) | -200,000 | $0.58 | $116k | 2,300,000 | Jul 10, 2025 |
| Jul 3, 2025 | ELTP ELITE PHARMACEUTICALS INC /NV/ | MOption exercise Stock Options (right to buy) | +2,500,000 | $0.03 | $75k | 2,500,000 | Jul 8, 2025 |
| Jul 3, 2025 | ELTP ELITE PHARMACEUTICALS INC /NV/ | MOption exercise Stock Options (right to buy)derivative | -2,500,000 | $0.00 | $0 | 5,000,000 | Jul 8, 2025 |
| Oct 23, 2024 | ELTP ELITE PHARMACEUTICALS INC /NV/ | SOpen-market sale Common Stock | -800,000 | $0.49 | $392k | 333,932 | Oct 28, 2024 |
| Oct 24, 2024 | ELTP ELITE PHARMACEUTICALS INC /NV/ | SOpen-market sale Common Stock | -333,932 | $0.51 | $170k | 0 | Oct 28, 2024 |
Questions about Douglas Plassche
Answered from the filings on this page, as of the latest one.
Is Douglas Plassche buying or selling?
Not in the last 12 months. Douglas Plassche's latest open-market trade on SEC Form 4 was sold $499k of ELTP on Oct 2, 2025.
How did Douglas Plassche's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas Plassche has 0.
Where does Douglas Plassche file Form 4?
Douglas Plassche has filed Form 4 at ELTP (ELITE PHARMACEUTICALS INC /NV/) as EVP Operations. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.